MorphoSys has received a clinical milestone payment from Bayer, relating to the launch of a Phase II clinical trial on a candidate treatment for rare cancer mesothelioma. The candidate, anetumab ravtansine (BAY 94-9343), was developed by Bayer using the MorphoSys Human Combinatorial Antibody Library (HuCAL) technology, which involves the in-vitro generation of distinct fully human antibodies. Anetumab ravtansine was the fourth antibody developed using the HuCAL technology platform to move into decisive phases of clinical development.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
67.75 EUR | 0.00% | +0.15% | +99.26% |
15/07 | MorphoSys Informs Nasdaq Stock Market of Delisting Plans After Novartis Merger | MT |
12/07 | Novartis Seeks Squeeze Out Approval at MorphoSys AGM | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+99.26% | 277.69Cr | |
+25.83% | 4.8TCr | |
+45.55% | 4.15TCr | |
+0.69% | 4.24TCr | |
+30.52% | 3.16TCr | |
+22.30% | 2.86TCr | |
-6.35% | 2.8TCr | |
+49.25% | 1.46TCr | |
+49.18% | 1.41TCr | |
+3.45% | 1.26TCr |
- Stock Market
- Equities
- MOR Stock
- News MorphoSys AG
- MorphoSys Earns Milestone Payment as Bayer Launches Phase II Trial of Mesothelioma Candidate